The multivalent activity of the tissue factor-thrombin pathway in thrombotic and non-thrombotic disorders as a target for therapeutic intervention.
Title | The multivalent activity of the tissue factor-thrombin pathway in thrombotic and non-thrombotic disorders as a target for therapeutic intervention. |
Publication Type | Journal Article |
Year of Publication | 2011 |
Authors | Mitroulis, I., Kambas K., Anyfanti P., Doumas M., & Ritis K. |
Journal | Expert Opin Ther Targets |
Volume | 15 |
Issue | 1 |
Pagination | 75-89 |
Date Published | 2011 Jan |
ISSN | 1744-7631 |
Keywords | Animals, Anticoagulants, Blood Coagulation, Drug Delivery Systems, Hemostasis, Heparin, Low-Molecular-Weight, Humans, Thrombin, Thromboplastin, Thrombosis |
Abstract | IMPORTANCE OF THE FIELD: Tissue factor (TF) is the key initiator of the coagulation cascade. The exposure of subendothelial TF after vessel injury to blood is a critical step in hemostasis and in the pathogenesis of arterial and venous thrombotic disorders. Moreover, an additional role for TF overexpression and subsequent generation of TF:FVIIa complex, FXa and thrombin have been recently emerged, contributing in non-thrombotic manifestations such as inflammation, cancer growth and fibrosis.AREAS COVERED IN THIS REVIEW: The multivalent role of TF and the above mentioned proteases in disease is reviewed, with focus on their implication in non-thrombotic disorders, as suggested by clinical and experimental data. Moreover, potential therapeutic interventions using anticoagulation agents are discussed.WHAT THE READER WILL GAIN: A better understanding of the pathogenic role of the TF-thrombin pathway in the pathogenesis of disease and the effect of anticoagulants in the treatment of such disorders.TAKE HOME MESSAGE: The TF-thrombin pathway, apart from the initiation of hemostasis and thrombosis, exert intracellular signaling activity through protease-activated receptors, participating in inflammation and tumor biology. Both low-molecular-weight heparins and recently developed anticoagulants rise as candidates for the modification of biological functions associated with disorders like sepsis, ischemia-reperfusion or cancer growth and metastasis. |
DOI | 10.1517/14728222.2011.532788 |
Alternate Journal | Expert Opin. Ther. Targets |
PubMed ID | 21062231 |